Document is current
Any future updates will be listed below
-
Authors
Jia, Xiaoming https://orcid.org/0000-0001-7949-6173
Lee, Michelle T.
Ramsey, David J.
Al Rifai, Mahmoud
Mahtta, Dhruv
Krittanawong, Chayakrit
Akeroyd, Julia M.
Matheny, Michael E.
Gobbel, Glenn
Stone, Neil J.
Ballantyne, Christie M.
Petersen, Laura A.
Virani, Salim S.
-
Funding
Funding for this research was provided by:
Department of Veterans Affairs Health Services Research & Development Service Investigator Initiated Grant (IIR 16–072)
American Heart Association (14BGIA20460366)
American Diabetes Association Clinical Science and Epidemiology award (1-14- CE-44)
Houston VA Health Services Research & Development Center for Innovations grant (CIN13-413)
- License Information
-
More Information
Article History
Accepted: 19 January 2021
First Online: 1 February 2021
Declarations
:
: The institutional review boards at Baylor College of Medicine and the Michael E. DeBakey VA Medical Center approved the study protocol. An approval was also obtained for the informed consent waiver.
: Xiaoming Jia, Michelle T. Lee, David J. Ramsey, Mahmoud Al Rifai, Dhruv Mahtta, Chayakrit Krittanawong, Julia M. Akeroyd, Michael E. Matheny, Glenn Gobbel, Neil J. Stone, Laura A. Petersen: none. Christie M. Ballantyne: grant/research support—all significant. (All paid to institution, not individual): Akcea, Amgen, Esperion, Novartis, Regeneron, Sanofi-Synthelabo, NIH, AHA, ADA. Consultant—Abbott Diagnostics, Akcea, Amarin, Amgen, Arrowhead, Astra Zeneca, Corvidia, Denka Seiken, Esperion, Intercept, Matinas BioPharma Inc., Merck, Novartis, Regeneron, Sanofi-Synthelabo. Salim S. Virani: honorarium, American College of Cardiology (Associate Editor for Innovations, ); Steering Committee, Patient and Provider Assessment of Lipid Management (PALM registry) at the Duke Clinical Research Institute (no financial remuneration).
: The opinions expressed reflect those of the authors and not necessarily those of the Department of Veterans Affairs or the US government.
